1
|
Zahednezhad F, Allahyari S, Sarfraz M, Zakeri-Milani P, Feyzizadeh M, Valizadeh H. Liposomal drug delivery systems for organ-specific cancer targeting: early promises, subsequent problems, and recent breakthroughs. Expert Opin Drug Deliv 2024; 21:1363-1384. [PMID: 39282895 DOI: 10.1080/17425247.2024.2394611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Accepted: 08/16/2024] [Indexed: 10/02/2024]
Abstract
INTRODUCTION Targeted liposomal systems for cancer intention have been recognized as a specific and robust approach compared to conventional liposomal delivery systems. Cancer cells have a unique microenvironment with special over-expressed receptors on their surface, providing opportunities for discovering novel and effective drug delivery systems using active targeting. AREAS COVERED Smartly targeted liposomes, responsive to internal or external stimulations, enhance the delivery efficiency by increasing accumulation of the encapsulated anti-cancer agent in the tumor site. The application of antibodies and aptamers against the prevalent cell surface receptors is a potent and ever-growing field. Moreover, immuno-liposomes and cancer vaccines as adjuvant chemotherapy are also amenable to favorable immune modulation. Combinational and multi-functional systems are also attractive in this regard. However, potentially active targeted liposomal drug delivery systems have a long path to clinical acceptance, chiefly due to cross-interference and biocompatibility affairs of the functionalized moieties. EXPERT OPINION Engineered liposomal formulations have to be designed based on tissue properties, including surface chemistry, charge, and microvasculature. In this paper, we aimed to investigate the updated targeted liposomal systems for common cancer therapy worldwide.
Collapse
Affiliation(s)
- Fahimeh Zahednezhad
- Student Research Committee and Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran
| | - Saeideh Allahyari
- Department of Pharmaceutics, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran
| | | | - Parvin Zakeri-Milani
- Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Mohammad Feyzizadeh
- Student Research Committee and Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran
| | - Hadi Valizadeh
- Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran
| |
Collapse
|
2
|
Ediriweera GR, Simpson JD, Fuchs AV, Venkatachalam TK, Van De Walle M, Howard CB, Mahler SM, Blinco JP, Fletcher NL, Houston ZH, Bell CA, Thurecht KJ. Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery. Chem Sci 2020; 11:3268-3280. [PMID: 34122834 PMCID: PMC8157365 DOI: 10.1039/d0sc00078g] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
There remain several key challenges to existing therapeutic systems for cancer therapy, such as quantitatively determining the true, tissue-specific drug release profile in vivo, as well as reducing side-effects for an increased standard of care. Hence, it is crucial to engineer new materials that allow for a better understanding of the in vivo pharmacokinetic/pharmacodynamic behaviours of therapeutics. We have expanded on recent “click-to-release” bioorthogonal pro-drug activation of antibody-drug conjugates (ADCs) to develop a modular and controlled theranostic system for quantitatively assessing site-specific drug activation and deposition from a nanocarrier molecule, by employing defined chemistries. The exploitation of quantitative imaging using positron emission tomography (PET) together with pre-targeted bioorthogonal chemistries in our system provided an effective means to assess in real-time the exact amount of active drug administered at precise sites in the animal; our methodology introduces flexibility in both the targeting and therapeutic components that is specific to nanomedicines and offers unique advantages over other technologies. In this approach, the in vivo click reaction facilitates pro-drug activation as well as provides a quantitative means to investigate the dynamic behaviour of the therapeutic agent. There remain several key challenges to existing therapeutic systems for cancer therapy, such as quantitatively determining the true, tissue-specific drug release profile in vivo, as well as reducing side-effects for an increased standard of care.![]()
Collapse
Affiliation(s)
- Gayathri R Ediriweera
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| | - Joshua D Simpson
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| | - Adrian V Fuchs
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| | - Taracad K Venkatachalam
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| | - Matthias Van De Walle
- School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology 2 George St Brisbane QLD 4000 Australia
| | - Christopher B Howard
- Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Training Centre for Biopharmaceutical Innovation, The University of Queensland Brisbane QLD 4072 Australia
| | - Stephen M Mahler
- Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Training Centre for Biopharmaceutical Innovation, The University of Queensland Brisbane QLD 4072 Australia
| | - James P Blinco
- School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology 2 George St Brisbane QLD 4000 Australia
| | - Nicholas L Fletcher
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| | - Zachary H Houston
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| | - Craig A Bell
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| | - Kristofer J Thurecht
- Centre for Advanced Imaging, The University of Queensland Brisbane QLD 4072 Australia .,Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland Brisbane QLD 4072 Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane QLD 4072 Australia
| |
Collapse
|
3
|
Surface engineering of nanomaterials with phospholipid-polyethylene glycol-derived functional conjugates for molecular imaging and targeted therapy. Biomaterials 2019; 230:119646. [PMID: 31787335 DOI: 10.1016/j.biomaterials.2019.119646] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 11/16/2019] [Accepted: 11/21/2019] [Indexed: 12/12/2022]
Abstract
In recent years, phospholipid-polyethylene glycol-derived functional conjugates have been widely employed to decorate different nanomaterials, due to their excellent biocompatibility, long blood circulation characteristics, and specific targeting capability. Numerous in vivo studies have demonstrated that nanomedicines peripherally engineered with phospholipid-polyethylene glycol-derived functional conjugates show significantly increased selective and efficient internalization by target cells/tissues. Targeting moieties including small-molecule ligands, peptides, proteins, and antibodies are generally conjugated onto PEGylated phospholipids to decorate liposomes, micelles, hybrid nanoparticles, nanocomplexes, and nanoemulsions for targeted delivery of diagnostic and therapeutic agents to diseased sites. In this review, the synthesis methods of phospholipid-polyethylene glycol-derived functional conjugates, biophysicochemical properties of nanomedicines decorated with these conjugates, factors dominating their targeting efficiency, as well as their applications for in vivo molecular imaging and targeted therapy were summarized and discussed.
Collapse
|
4
|
Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Ther 2017; 24:441-452. [PMID: 28504657 DOI: 10.1038/gt.2017.41] [Citation(s) in RCA: 127] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 05/08/2017] [Accepted: 05/10/2017] [Indexed: 02/07/2023]
Abstract
Recent mechanistic studies have attempted to deepen our understanding of the process by which liposome-mediated delivery of genetic material occurs. Understanding the interactions between lipid nanoparticles and cells is still largely elusive. Liposome-mediated delivery of genetic material faces systemic obstacles alongside entry into the cell, endosomal escape, lysosomal degradation and nuclear uptake. Rational design approaches for targeted delivery have been developed to reduce off-target effects and enhance transfection. These strategies, which have included the modification of lipid nanoparticles with target-specific ligands to enhance intracellular uptake, have shown significant promise at the proof-of-concept stage. Control of physical and chemical specifications of liposome composition, which includes lipid-to-DNA charge, size, presence of ester bonds, chain length and nature of ligand complexation, is integral to the performance of targeted liposomes as genetic delivery agents. Clinical advances are expected to rely on such systems in the therapeutic application of liposome nanoparticle-based gene therapy. Here, we discuss the latest breakthroughs in the development of targeted liposome-based agents for the delivery of genetic material, paying particular attention to new ligand and cationic lipid design as well as recent in vivo advances.
Collapse
Affiliation(s)
| | | | - S Pasley
- Akron Biotech, Boca Raton, FL, USA
| | | |
Collapse
|
5
|
Kim H, Lee KH, Kim KB, Park YS, Kim KS, Kim DE. Antiviral Efficacy of a Short PNA Targeting microRNA-122 Using Galactosylated Cationic Liposome as a Carrier for the Delivery of the PNA-DNA Hybrid to Hepatocytes. B KOREAN CHEM SOC 2013. [DOI: 10.5012/bkcs.2013.34.3.735] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|